News and insights

Subscribe to our newsletter

Massachusetts General Hospital (MGH), the Ó³»­´«Ã½, and Amgen (NASDAQ:AMGN) announced today that they have launched a strategic collaboration to jointly discover and validate new therapeutic targets and develop novel therapies for inflammatory bowel disease (IBD), a chronic disorder that affects millions worldwide. The MGH-Ó³»­´«Ã½-Amgen collaboration brings together scientists with expertise in clinical medicine, IBD biology, human genetics, genomic technology, and drug discovery to work together to help create a new world of therapeutic options for IBD patients.

The most comprehensive genetic study to date of the blood cancer multiple myeloma has revealed that the genetic landscape of the disease may be more complicated than previously thought. Through results published in Cancer Cell today, a team of Ó³»­´«Ã½ researchers has shown that an individual patient’s tumor can harbor populations of cancer cells equipped with different mutations. These findings could have therapeutic implications for patients in the future.

The annual Forbes was revealed this week, and two members of the Ó³»­´«Ã½ community, Cigall Kadoch and Aleksander Kostic, were named to the list. Now in its third year, ’30 under 30’ recognizes the brightest young talents in 15 different fields, including science and healthcare, technology and finance.

Cervical cancer

Researchers from the Boston area, Mexico, and Norway have completed a comprehensive genomic analysis of cervical cancer in two patient populations. The study identified recurrent genetic mutations not previously found in cervical cancer, including at least one for which targeted treatments have been approved for other forms of cancer. The findings also shed light on the role human papillomavirus (HPV) plays in the development of cervical cancer.